CD4 and neoplasm: As shown in Fig. 5b, the proportion of activated CD4+ T effector cells increased in the tumor region after ipilimumab treatment in one respond patient (P7), and decreased in the tumor region after ipilimumab treatment in one non-respond patient (P8).